Wound Care Biologics Market Share

  • Report ID: 6256
  • Published Date: Jun 27, 2024
  • Report Format: PDF, PPT

Wound Care Biologics Market Share

North American Market Statistics

North America region in wound care biologics market is anticipated to account for revenue share of around 45.1% by 2036. This rise is poised to be encouraged by a growing number of wound care procedures.  As a consequence, wound care biologics are expected to be a growing business, which encompasses topical treatments and skin grafts composed of bioengineered cells. Particularly, in 2022, more than 12,880,540 wound dressing procedures were carried out over North America.

One of the main causes of unintended death in the United States is burns, which is likely to augment market demand for wound care biologics.  According to the American Burn Association’s Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS), there are approximately 30,000 burn admissions per year (weighted estimates), representing 88.5 admissions per million lives per year.

In Canada, the market for wound care biologics is anticipated to expand since the prioritization of wound treatment is becoming more widely recognized among Canadian healthcare institutions.

European Market Analysis

The Europe region is estimated to account for the second-largest revenue share in the wound care biologics market through 2036. Majority of European nations now have universal health coverage, making the health care industry one of the fast-growing regions in the world.  More than 55% of prescription drug expenditures in the EU are paid for by mandatory or governmental insurance programs.

In Germany, a new wound dressing called Epicite Balance was introduced by JeNaCell in June 2023, an Evonik business, using hydro polymer called biosynthetic cellulose for creative uses in medical devices. he dressing is especially well-suited and adapted for the management of chronic wounds which impact around 1% of people in developed nations, particularly elderly patients.

Also, more than 20% of Italians out of the country's total population are said to suffer from chronic ulcers, leading to market expansion.

Research Nester
Wound Care Biologics
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6256
  • Published Date: Jun 27, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of wound care biologics was over USD 2.7 billion.

The market size for wound care biologics is projected to cross USD 6.7 billion by the end of 2036 expanding at a CAGR of 9% during the forecast period i.e., between 2024-2036.

The major players in the market are Smith & Nephew, Molnlycke Health Care AB, Integra LifeSciences Corporation, Wright Medical Group N.V., MiMedx Group, Inc., Vericel Corporation, Anika Therapeutics, Osiris Therapeutics, Inc., Solsys Medical, LLC, Lavior Pharma Inc., and others.

In terms of wound type, the ulcers segment is anticipated to account for the largest market share of 45% during 2024-2036.

The North America wound care biologics sector is poised to hold the highest share of 45% by 2036.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample